Nanotechnologies for the treatment of colon cancer: From old drugs to new hope - ScienceDirect
Current Oncology | Free Full-Text | A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer | NEJM
LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy
These highlights do not include all the information needed to use LONSURF safely and effectively. See full prescribing information for LONSURF. LONSURF (trifluridine and tipiracil) tablets, for oral use Initial U.S. Approval:
La trifluridine plus le tipiracil et le bévacizumab est une nouvelle norme de soins pour le cancer colorectal métastatique réfractaire
Trifluridine/Tipiracil Combination Misses Mark in Metastatic Colon Cancer | MedPage Today
La trifluridine plus le tipiracil et le bévacizumab est une nouvelle norme de soins pour le cancer colorectal métastatique réfractaire
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
How does chemo fit into my treatment plan? - Colontown University
NCCN® Guidelines for Metastatic Colon Cancer Treatment
4. Cancer colorectal métastatique | SNFGE.org - Société savante médicale française d'hépato-gastroentérologie et d'oncologie digestive
Adding Avastin to Lonsurf Improved Outcomes in Pretreated Colorectal Cancer
Benefits & Risks of Treatment | Metastatic Colorectal Cancer (mCRC)| Avastin® (bevacizumab)
NEJM on X: "This editorial describes the science behind a clinical trial performed by Prager and colleagues: a test of trifluridine–tipiracil and bevacizumab to treat patients with refractory metastatic colorectal cancer. https://t.co/Y1QlV28qsr" /
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
Taiho Oncology et Servier annoncent la publication dans le New England Journal of Medicine des données de l'étude pivot de phase 3 sur l'association trifluridine/tipiracil (LONSURF®) plus bévacizumab chez le patients atteint
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer | NEJM
Continued Avastin Extends Survival After 1st Progression in Colorectal Cancer - CancerConnect
Avastin® (bevacizumab) Dosing | MCRC Treatment
Servier et Taiho Oncology présentent des données sur la survie globale de trifluridine/tipiracil (LONSURF®) en association avec le bevacizumab chez des patients atteints d'un cancer colorectal métastatique réfractaire... | Business Wire
Servier et Taiho Oncology présentent des données sur la survie globale de trifluridine/tipiracil (LONSURF®) en association avec le bevacizumab chez des patients atteints d'un cancer colorectal métastatique réfractaire... | Business Wire
Servier : AMM européenne pour LONSURF en association au bevacizumab dans le cancer colorectal métastatique réfractaire | MyPharma Editions
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
How does chemo fit into my treatment plan? - Colontown University
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
